Editas Medicine, Inc.: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 4, 2018 and accepted by EDGAR at May 4, 2018, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2018-01-01 to 2018-03-31 | $21.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$31.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$30.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | −$0.67 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2018-01-01 to 2018-03-31 | −$22.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2018-01-01 to 2018-03-31 | $1.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-03-31 | $217.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-03-31 | $362.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $404.0m | us-gaap:Assets |
| Current liabilities | At period end2018-03-31 | $31.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-03-31 | $156.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-03-31 | $247.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-18-004024. Last ingested by Listed: Nov 6, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.